Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points

Nutriband Inc. announced key milestones from its January 2026 Annual Shareholders Meeting, including the addition of two new directors with strong financial and operational backgrounds. The company reported progress on its AVERSA™ abuse-deterrent fentanyl patch development, including patent grants, manufacturing scale-up completion, and FDA Type C meeting. However, the proposed sale of its Pocono Pharma subsidiary to EarthVision Bio remains incomplete, with the company collecting weekly penalty payments. Nutriband also filed a FINRA complaint regarding suspected naked short selling and reminded shareholders of warrant expiration in October 2026.

01/30/2026, 7:00 AM • GlobeNewswire

Nutriband CEO Publishes Letter to Shareholders

Nutriband Inc. reported significant progress in 2025 including the sale of 90% of its Pocono subsidiary to EarthVision Bio for $5M with no shareholder dilution, a 25% preferred stock dividend, and major advances in its lead product AVERSA Fentanyl abuse-deterrent patch. The company received FDA Type C Meeting approval, completed manufacturing scale-up, secured additional patents, and was added to four Russell indexes. The CEO highlighted shareholder value focus and anticipated warrant expiration in October 2026 as a potential positive catalyst.

12/31/2025, 7:00 AM • GlobeNewswire

Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio

Nutriband Inc. announced the sale of a 90% stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million USD, with Nutriband shareholders retaining 10% ownership. The company plans to use proceeds to develop AVERSA Fentanyl, an abuse-deterrent opioid patch with potential annual US sales of $80-200 million. EarthVision Bio is developing sustainable product alternatives founded by Intel co-founder Dr. Gordon Moore and ex-Chevron Europe chairman Dr. Hans Franke.

12/29/2025, 9:00 AM • GlobeNewswire

Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Nutriband met with the FDA to discuss its AVERSA™ FENTANYL abuse deterrent patch, receiving guidance on regulatory pathway, manufacturing, and clinical study plans for a potential first-of-its-kind worldwide abuse deterrent fentanyl patch.

10/28/2025, 7:00 AM • GlobeNewswire

Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

Nutriband has partnered with Brand Institute to develop a commercial brand name for its lead product, an abuse deterrent fentanyl transdermal patch utilizing AVERSA™ technology, aimed at preventing drug misuse and accidental exposure.

10/10/2025, 7:00 AM • GlobeNewswire

Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream

EmergingGrowth.com announced the schedule for its 85th conference featuring presentations from multiple public companies across various sectors on August 20-21, 2025, providing insights into emerging growth companies.

08/20/2025, 7:00 AM • GlobeNewswire

FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

Nutriband Inc. received FDA meeting approval to discuss Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL, an abuse-deterrent fentanyl patch developed in partnership with Kindeva. The product aims to prevent drug abuse and misuse while maintaining patient accessibility.

08/08/2025, 8:00 AM • GlobeNewswire

Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval

Nutriband Inc. announced a 25% preferred stock dividend for shareholders, with record date on July 25th, 2025 and pay date on August 5th. The preferred shares are convertible to common stock upon FDA approval of their AVERSA Fentanyl product.

07/18/2025, 9:15 AM • Benzinga